CN115073425B - 一类作为tbk1抑制剂的化合物、包含其的药物组合物及其用途 - Google Patents
一类作为tbk1抑制剂的化合物、包含其的药物组合物及其用途 Download PDFInfo
- Publication number
- CN115073425B CN115073425B CN202110280860.5A CN202110280860A CN115073425B CN 115073425 B CN115073425 B CN 115073425B CN 202110280860 A CN202110280860 A CN 202110280860A CN 115073425 B CN115073425 B CN 115073425B
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- compound
- mmol
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 105
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 title claims abstract description 43
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 title claims abstract description 43
- 239000003112 inhibitor Substances 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 4
- -1 (2-aminophenyl) carbamoyl Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 5
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical class 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical class 0.000 claims description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical class [H]C([H])([H])* 0.000 claims description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 2
- 125000003003 spiro group Chemical group 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 65
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 31
- 238000005481 NMR spectroscopy Methods 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 28
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 22
- 238000004440 column chromatography Methods 0.000 description 22
- 238000001035 drying Methods 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000001284 I-kappa-B kinase Human genes 0.000 description 3
- 108060006678 I-kappa-B kinase Proteins 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 108091054729 IRF family Proteins 0.000 description 2
- 102000016854 Interferon Regulatory Factors Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical group [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 1
- WLODWTPNUWYZKN-UHFFFAOYSA-N 1h-pyrrol-2-ol Chemical group OC1=CC=CN1 WLODWTPNUWYZKN-UHFFFAOYSA-N 0.000 description 1
- AOTQGWFNFTVXNQ-UHFFFAOYSA-N 2-(1-adamantyl)acetic acid Chemical compound C1C(C2)CC3CC2CC1(CC(=O)O)C3 AOTQGWFNFTVXNQ-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- FFPHMUIGESPOTK-UHFFFAOYSA-N 4-[[[5-bromo-2-[[3-methyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]methyl]benzenesulfonamide Chemical compound Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(cc2)S(N)(=O)=O)n1 FFPHMUIGESPOTK-UHFFFAOYSA-N 0.000 description 1
- PKCHRWPMNDRVMI-UHFFFAOYSA-N 5-bromo-2-(bromomethyl)pyridine Chemical compound BrCC1=CC=C(Br)C=N1 PKCHRWPMNDRVMI-UHFFFAOYSA-N 0.000 description 1
- YRKLTEBZMAAPHL-UHFFFAOYSA-N 5-pyrimidin-4-yl-2-pyrrolidin-1-ylpyridine-3-carbonitrile Chemical class N1=CN=C(C=C1)C=1C=NC(=C(C#N)C=1)N1CCCC1 YRKLTEBZMAAPHL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 101001117144 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) [Pyruvate dehydrogenase (acetyl-transferring)] kinase 1, mitochondrial Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- HHRFWSALGNYPHA-UHFFFAOYSA-N [N].C1CNCCN1 Chemical group [N].C1CNCCN1 HHRFWSALGNYPHA-UHFFFAOYSA-N 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- SGRYPYWGNKJSDL-UHFFFAOYSA-N amlexanox Chemical compound NC1=C(C(O)=O)C=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=N1 SGRYPYWGNKJSDL-UHFFFAOYSA-N 0.000 description 1
- 229960003731 amlexanox Drugs 0.000 description 1
- 150000001565 benzotriazoles Chemical class 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一类作为TBK1抑制剂的化合物、包含其的药物组合物及其用途。所述化合物由以下通式I表示,所述通式I的化合物具有显著的TBK1抑制活性,具备开发成TBK1抑制剂类药物以及与TBK1相关疾病,例如恶性肿瘤、自身免疫及炎症疾病的治疗药物的潜力。
Description
技术领域
本发明属于药物化学领域,具体涉及一类可作为TBK1抑制剂的化合物、包含其的药物组合物及其制药用途。
背景技术
TANK结合激酶1(TANK binding kinase1,TBK1)隶属丝氨酸/苏氨酸蛋白,属于非经典的IκB激酶(IKK)家族。TBK1参与调控干扰素调节因子(IRF)、核因子κB(NF-κB)、I型干扰素(IFN-I)、II型干扰素(IFN-II)靶基因等多条信号通路和转录因子,以及STING介导的胞质DNA检测,调节抗病毒防御、宿主-病毒相互作用,在免疫、肿瘤、炎症、代谢等疾病的发生和发展过程中发挥重要作用。近年来,由于其在肿瘤免疫治疗中发挥的重要作用,TBK1小分子抑制剂的研究成为了热点,但由于TBK1与IKKε的氨基酸序列具有较高相似性,其选择性及脱靶造成的毒副作用成为了靶向TBK1药物研发的难点。
目前TBK1抑制剂的研发尚处于早期,一方面由于TBK1的生物学功能及作用机制尚未完全明确;另一方面TBK1抑制剂结构类型少,选择性TBK1抑制剂尚未进入临床研究。现有的TBK1抑制剂大多具有多个靶点,如由武田药品工业株式会社研发的BX795(Amlexanox)作为PDK1抑制剂上市,后来发现其对TBK1以及IKKε表现相当水平的抑制活性(PDK1 IC50=17nM,TBK1 IC50=2.3nM,IKKεIC50=9.5nM)[Biochem.J.(2007)408,297-315]。GSK8612是葛兰素史克2019年报道的选择性TBK1抑制剂,尽管它对于IKK激酶具有10倍的选择性,对TBK1激酶的活性(TBK1 pIC50=6.8)不佳导致其尚未进入临床研究。Domainex公司公开的专利申请WO2018154315A1中,实施例2具有良好的TBK1激酶抑制活性(IC50=20nM),但它依然同时靶向TBK1和IKKε(IKKεIC50=21nM)。由此可见,寻找高效的选择性TBK1小分子抑制剂仍十分必要且存在挑战性和必要性,因此,有必要对TBK1抑制剂进行深入的结构优化研究,从而获得一类具有高活性的TBK1抑制剂化合物。
发明内容
本发明的技术目的是提供一类可作为TBK1抑制剂的化合物、包含其的药物组合物及其制药用途。所述化合物对于TBK1表现出提高的抑制活性。
一方面,本发明提供一种由以下通式I表示的化合物、其药学上可接受的盐或药学上可接受的溶剂合物:
在以上通式I中,
Z选自C1-C8亚烷基;优选选自C1-C4亚烷基;
Q选自含有1~3个选自N、O、S杂原子的5~8元杂环基,所述杂环基包括单环、并环、桥环、螺环;优选选自哌嗪环,更优选选自/>
Y选自-C(=O)-R1,-(CH2)m-R2或-L-X,
其中,R1选自取代或未取代的C1-C6烷氧基、取代或未取代的C2-C6炔基、取代或未取代的C2-C6烯基、取代或未取代的5-10元杂芳基,优选地,R1选自取代或未取代的C1-C4烷氧基、取代或未取代的C2-C4炔基、取代或未取代的C2-C4烯基、取代或未取代的5-10元杂芳基,更优选选自取代或未取代的甲氧基,取代或未取代的乙氧基,取代或未取代的叔丁氧基,取代或未取代的乙炔基,取代或未取代的丙炔基,取代或未取代的乙烯基,取代或未取代的丙烯基,取代或未取代的所述取代的取代基选自卤素、C1-C6烷氧酰基、5-7元杂环基、(2-氨基苯基)胺甲酰基,优选选自卤素、C1-C4烷氧酰基、吗啉基、(2-氨基苯基)胺甲酰基,更优选选自氟、氯、溴、甲氧酰基、乙氧酰基、吗啉基、(2-氨基苯基)胺甲酰基;
m为1-4的整数,
R2选自取代或未取代的C6-C10芳基、-NHC(=O)-R3,优选地,R2选自取代或未取代的苯基、-NHC(=O)-R3,其中,C6-C10芳基或苯基的取代基选自未取代或被卤素取代的磺酰基,R3选自C1-C6烷氧基、未取代或金刚烷取代的C1-C6烷基,优选地,R3选自C1-C4烷氧基、未取代或金刚烷取代的C1-C4烷基,更优选地,R3选自甲氧基、乙氧基、叔丁氧基、甲基、乙基、金刚烷取代的甲基、金刚烷取代的乙基;
L选自-[-(CH2)2-O]n-(CH2)f-、-(CH2)n-NH-C(=O)-CH2-O-(CH2)2-O-CH2-、-(CH2)n-NH-C(=O)-CH2-[O-(CH2)2]p-NH-C(=O)-(CH2)q-,其中n、f、p和q各自独立地为0至6的整数,例如1、2、3、4等,
X为
在具体实施方式中,
Z为C1-C4亚烷基;
Q选自
Y的定义如上所述。
在具体实施方式中,
Z为-CH2-;
Q为
Y的定义如上所述。
在具体实施方式中,
所述通式I的化合物可由以下通式II表示:
其中,在上述通式II中,L和X的定义分别同上文所定义。
在具体实施方式中,所述通式I的化合物可选自以下化合物之一:
另一方面,本发明提供了一种药物组合物,其至少包含上述通式I的化合物、其药学上可接受的盐或药学上可接受的溶剂合物作为药物活性组分,以及药学上可接受的载体。
再一方面,本发明提供上述通式I的化合物、其药学上可接受的盐或药学上可接受的溶剂合物,或上述药物组合物在制备用作TBK1抑制剂的药物中的用途。
在具体实施方式中,所述TBK1抑制剂可用于恶性肿瘤、自身免疫及炎症疾病的治疗。
根据本发明,所述术语的定义如下:
烷基均表示直链或支链脂肪族饱和烃基。
亚烷基是指衍生自烷基的二价基团。
烯基表示具有1个、2个或3个碳-碳双键的直链或支链脂肪族不饱和烃基。
炔基表示具有含有1个、2个或3个碳-碳三键的直链或支链脂肪族不饱和烃基。
烷氧基表示式-OR的基团,其中R为烷基。
杂环基表示具有环碳原子和1-3个选自氮、氧、硫的环杂原子的非芳族环基团,例如5-8元杂环基表示环碳原子和环杂原子数为5-8的非芳族环基团,包括但不限于哌嗪环、吗啉环、哌啶环、吡咯环、羟基吡咯环、羟基哌啶。
芳基表示具有在芳香环系统中提供的碳原子和0个杂原子的单环或多环芳香环基团,例如,C6-10芳基表示具有6-10个芳香环碳原子的单环或多环芳香环基团,包括但不限于苯基、萘基。
杂芳基表示具有在芳族环系统中提供的环碳原子和1-3个选自氮、氧、硫的环杂原子的单环或多环基团,例如,5-10元杂芳基表示芳族环碳原子和环杂原子数为5-10的单环或多环芳香基团,包括但不限于吡啶环、噻吩环、苯并三氮唑。
有益效果
本申请设计的一类新型化合物相较于现有技术的具有类似结构5-(嘧啶-4-基)-2-(吡咯烷-1-基)烟腈化合物显示出显著提高的TBK1抑制活性,因此,具备开发成TBK1抑制剂类药物以及与TBK1相关疾病,例如恶性肿瘤、自身免疫及炎症疾病的治疗药物的潜力。
附图说明
图1示出在实验例中测定各化合物的TBK1激酶抑制活性的原理图。
具体实施方式
下面结合具体实施例对本发明作进一步阐述,但这些实施例并不限制本发明的范围。
对于以下实施例,可以使用本领域技术人员已知的标准操作和纯化方法。除非另有规定,否则原料通常是从市售来源可获得的。商购的溶剂和试剂一般在不进一步纯化的情况下使用,无水溶剂均通过标准方法处理,其他试剂为市售分析纯。除非另有说明,所有温度以℃(摄氏度)表示,室温或环境温度是指20~25℃。化合物的结构通过核磁共振谱(NMR)来确定的。核磁共振氢谱位移(δ)以百万分之一(ppm)的单位给出。核磁共振氢谱用Bruker-400MHz型核磁共振仪测定,氘代氯仿(CDCl3)、氘代甲醇(CD3OD)为溶剂,四甲基硅烷(TMS)为内标。
层析柱一般使用200~300目硅胶为载体。
在上述讨论和下述实施例中,下列缩写具有如下含义。如果某一缩写没有定义,则它具有通常被接受的含义。
DMSO为二甲亚砜
Pd2(dba)3为三(二亚苄基丙酮)二钯
Davephos为2-二环己膦基-2'-(N,N-二甲胺)-联苯
DIPEA为N,N-二异丙基乙胺
DMAP为4-二甲氨基吡啶
Pd(OAc)2为醋酸钯
Xantphos为4,5-双二苯基膦-9,9-二甲基氧杂蒽
EDCI为1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐
NaBH(OAc)3为醋酸硼氢化钠
1,4-Dioxane为1,4-二氧六环溶液
DMF为N,N-二甲基甲酰胺溶液
NaOtBu为叔丁醇钠
KOtBu为叔丁醇钾
制备实施例
实施例1:化合物S1的制备
将化合物1-1(1000mg,3.42mmol)和化合物1-2(1100mg,3.62mmol)溶于1,4-二氧六环(1,4-Dioxane)中,在氮气保护下,加入Pd2(dba)3(220mg,0.38mmol),Davephos(300mg,0.76mmol)和NaOtBu(540mg,5.60mmol),120℃反应过夜,反应结束,乙酸乙酯和水萃取,旋干有机层,柱层析纯化。1H NMR(400MHz,氘代氯仿)δ8.99(d,J=2.3Hz,1H),8.75-8.71(m,1H),8.44(d,J=5.3Hz,1H),8.40(d,J=2.3Hz,1H),8.25-8.20(m,1H),7.52-7.38(m,1H),7.05(d,J=5.3Hz,1H),5.39(dt,J=52.7,3.0Hz,1H),4.27-3.92(m,4H),3.67(s,2H),3.48(s,4H),2.56-2.37(m,5H),2.27-2.01(m,1H),1.45(s,9H).
实施例2:化合物S2的制备:
中间体2-1的制备:
将S1(1200mg,2.14mmol)溶于二氯甲烷中,在室温下加入三氟乙酸(2ml),待反应结束后,旋干溶剂,得到化合物2-1粗品。
S2的制备:
将化合物2-1(30mg,0.07mmol)溶于超干的二氯甲烷中,在室温下加入2-炔丁酸(10mg,0.12mmol),HATU(37mg,0.10mmol)和DIPEA(0.05ml,0.30mmol),待反应结束后,乙酸乙酯和水萃取,旋干有机层,柱层析纯化。1H NMR(400MHz,氘代氯仿)δ9.00(d,J=2.2Hz,1H),8.74(d,J=2.2Hz,1H),8.45(d,J=5.2Hz,1H),8.42(d,J=2.3Hz,1H),8.23(dd,J=8.4,2.4Hz,1H),7.39(d,J=8.4Hz,1H),7.29(s,1H),7.07(d,J=5.3Hz,1H),5.40(d,J=52.7Hz,1H),4.28-3.94(m,4H),3.82-3.76(m,2H),3.67(s,4H),2.60-2.53(m,2H),2.53-2.47(m,2H),2.47-2.40(m,1H),2.27-2.05(m,1H),2.00(s,3H).
实施例3:化合物S3的制备
将化合物3-1(10.5mg,0.04mmol),三光气(15.7mg,0.053mmol),DMAP(21.5mg,0.18mmol)溶于超干二氯甲烷中,在室温下搅拌,加入化合物2-1(20mg,0.04mmol),室温反应5h。待反应结束后,用水,乙酸乙酯萃取,旋干有机层,柱层析纯化。1H NMR(400MHz,氘代氯仿)δ9.01(d,J=2.2Hz,1H),8.77(s,1H),8.44(dd,J=13.6,3.6Hz,2H),8.25(dd,J=8.3,2.1Hz,1H),8.09(d,J=8.2Hz,1H),7.99(d,J=8.2Hz,1H),7.60(t,J=7.6Hz,1H),7.48-7.40(m,2H),7.31(s,1H),7.07(d,J=5.3Hz,1H),5.46(d,J=2.7Hz,1H),4.30-3.89(m,8H),3.74(d,J=10.5Hz,2H),2.75(s,4H),2.53-2.40(m,1H),2.16(dd,J=40.4,9.9Hz,1H).
实施例4:化合物S4的制备:
将化合物4-1(33mg,0.20mmol),三光气(25mg,0.09mmol),DIPEA(0.1ml,0.65mmol)溶于超干二氯甲烷中,在室温下搅拌1h,加入化合物2-1(60mg,0.13mmol),室温反应5h。待反应结束后,用水,乙酸乙酯萃取,旋干有机层,柱层析纯化。1H NMR(400MHz,氘代氯仿)δ9.00(d,J=2.3Hz,1H),8.77(d,J=2.4Hz,1H),8.46(d,J=5.3Hz,1H),8.41(d,J=2.3Hz,1H),8.26(dd,J=8.5,2.6Hz,1H),7.78-7.70(m,1H),7.42(d,J=8.4Hz,1H),7.07(d,J=5.3Hz,1H),5.78(hept,J=5.9Hz,1H),5.41(d,J=52.4Hz,1H),4.28-4.13(m,2H),4.04(ddd,J=22.6,11.4,4.8Hz,2H),3.72(s,2H),3.67-3.60(m,4H),2.61(s,4H),2.47(td,J=16.6,15.7,5.7Hz,1H),2.28-2.05(m,1H).
实施例5:化合物S5的制备:
在冰浴条件下向二氯甲烷溶解的化合物2-1(60mg,0.13mmol)溶液中加入吡啶(11.4mg,0.14mmol)在逐滴加入化合物5-1(13mg,0.14mmol),半小时后移至室温反应约2h。待反应结束后,用水,乙酸乙酯萃取,旋干有机层,柱层析纯化。1H NMR(400MHz,氘代氯仿)δ8.98(d,J=2.4Hz,1H),8.73(d,J=2.4Hz,1H),8.44(d,J=5.3Hz,1H),8.39(d,J=2.4Hz,1H),8.23(dd,J=8.5,2.6Hz,1H),7.63(s,1H),7.38(d,J=8.4Hz,1H),7.04(d,J=5.3Hz,1H),6.55(dd,J=16.8,10.5Hz,1H),6.27(dd,J=16.8,1.9Hz,1H),5.67(dd,J=10.6,1.9Hz,1H),5.45(s,1H),4.26-3.92(m,4H),3.73(s,2H),3.66(s,2H),3.59(s,2H),2.57-2.50(m,4H),2.44(dt,J=15.9,7.4Hz,1H),2.05(s,1H).
实施例6:化合物S6的制备:
将化合物6-1(8mg,0.09mmol),HATU(49mg,0.13mmol),三乙胺(0.03ml,0.19mmol)溶于二氯甲烷中,再向其中加入化合物2-1(30mg,0.07mmol),室温反应,待反应结束后,使用水和二氯甲烷萃取,旋干有机层,柱层析纯化。1H NMR(400MHz,氘代氯仿)δ8.99(s,1H),8.73(s,1H),8.42(d,J=18.4Hz,2H),8.24(d,J=6.1Hz,1H),7.61(s,1H),7.38(d,J=9.4Hz,1H),7.04(s,1H),5.53-5.02(m,3H),4.29-3.90(m,4H),3.66(s,6H),2.49(d,J=43.0Hz,5H),2.28-2.00(m,1H).
实施例7:化合物S7的制备:
将化合物2-1(40mg,0.09mmol),化合物7-1(28mg,0.11mmol)和DIPEA(0.03ml,0.17mmol)溶于乙腈中,于室温反应5h。待反应结束后,乙酸乙酯和水萃取,旋干有机溶剂,柱层析纯化。1H NMR(400MHz,氘代氯仿)δ8.99(s,1H),8.72(s,1H),8.50-8.38(m,2H),8.21(d,J=8.2Hz,1H),7.94(d,J=7.9Hz,2H),7.61(d,J=8.0Hz,2H),7.40(d,J=8.4Hz,1H),7.34(s,1H),7.05(d,J=5.1Hz,1H),5.40(d,J=52.9Hz,1H),4.29-3.92(m,4H),3.65(d,J=22.1Hz,4H),2.53(t,J=23.0Hz,8H),2.28-2.03(m,2H).
实施例8:化合物S8的制备
中间体8-1的制备:
将5-溴-2-(溴甲基)吡啶(62mg,0.25mmol)溶于乙腈中,将3,8-二氮杂双环[3.2.1]辛烷-3-甲酸叔丁酯(58mg,0.28mmol)和三乙胺(0.12ml,0.83mmol)加入反应液中,室温反应2.5h;待反应结束,旋干溶剂,柱层析分离纯化。1H NMR(400MHz,氘代氯仿)δ8.56(s,1H),7.77(d,J=8.3Hz,1H),7.36(d,J=8.3Hz,1H),4.26-4.00(m,2H),3.57(s,2H),2.58(d,J=10.7Hz,2H),2.38(d,J=22.0Hz,2H),1.86(q,J=10.5,9.2Hz,4H),1.44(s,9H).
中间体8-3的制备:
将化合物8-1(678mg,1.77mmol),化合物8-2(二苯甲酮亚胺)(418mg,2.30mmol),Pd(OAc)2(24mg,0.11mmol),Xantphos(102mg,0.18mmol),KOtBu(298mg,2.66mmol)溶于1,4-Dioxane中,在N2保护下,转移至120℃反应5h,待反应结束,冷却至室温,水洗,乙酸乙酯萃取,旋干有机层,得到黑色油状物,将其溶于乙醇中,向其中加入盐酸羟胺(244mg,3.54mmol),乙酸钠(362.8mg,4.43mmol),室温搅拌2h,待反应结束,抽滤取滤液,旋干溶剂,用乙酸乙酯和0.5M NaOH溶液(50ml)萃取分离,用0.5M NaOH溶液洗有机层,再用乙酸乙酯(100ml,3次)洗合并后的NaOH溶液层。旋干有机层,柱层析纯化。1H NMR(400MHz,氘代氯仿)δ7.98(s,1H),7.17(d,J=8.3Hz,1H),6.96(dd,J=8.3,2.6Hz,1H),4.21-4.00(m,2H),3.49(s,2H),2.57(d,J=10.3Hz,2H),2.32(d,J=24.0Hz,2H),1.90-1.75(m,4H),1.43(s,9H).
S8的制备:
将化合物1-1(165mg,1.50mmol)和化合物8-3(531mg,1.67mmol)溶于1,4-二氧六环,在氮气保护下,加入Pd2(dba)3(137mg,0.15mmol),Davephos(118mg,0.30mmol)和NaOtBu(216mg,2.25mmol)120℃反应过夜,反应结束,乙酸乙酯和水萃取,旋干有机层,柱层析纯化。1H NMR(400MHz,氘代氯仿)δ8.99(s,1H),8.69(s,1H),8.48-8.38(m,2H),8.20(d,J=7.9Hz,1H),7.43(dd,J=18.2,7.9Hz,1H),7.04(d,J=5.0Hz,1H),5.39(d,J=52.8Hz,1H),4.29-3.92(m,7H),3.62(s,2H),2.64(d,J=10.4Hz,2H),2.53-2.28(m,1H),2.28-2.03(m,1H),1.89-1.74(m,5H),1.45(s,9H).
实施例9:化合物S9的制备
将化合物2-1(40mg,0.09mmol)和9-1(31mg,0.11mmol)溶于DMF中,加入DIPEA(0.03ml,0.17mmol),室温反应,待反应结束后,水和乙酸乙酯萃取,旋干有机层,柱层析纯化。1H NMR(500MHz,氘代氯仿)δ8.96(d,J=1.8Hz,1H),8.71(d,J=1.8Hz,1H),8.42(d,J=5.2Hz,1H),8.21(dd,J=8.3,2.7Hz,1H),7.70(s,1H),7.37(d,J=8.4Hz,1H),7.02(d,J=5.2Hz,1H),5.36(d,J=52.4Hz,1H),4.20(t,J=11.8Hz,2H),4.18-4.07(m,2H),3.99(ddd,J=22.9,16.7,11.0Hz,2H),3.77-3.65(m,4H),3.63(s,2H),3.49(s,4H),2.62(t,J=5.8Hz,2H),2.55-2.38(m,9H),2.24-2.03(m,1H).
实施例10:化合物S10的制备
将化合物2-1(100mg,0.22mmol),化合物10-1(34mg,0.26mmol),EDCI(84mg,0.44mmol),DMAP(6mg,0.05mmol)和DIPEA(0.1ml,0.66mmol)溶于二氯甲烷溶液中,室温搅拌,待反应结束后,用水和乙酸乙酯萃取,旋干有机相,柱层析纯化。1H NMR(600MHz,氘代甲醇)δ9.02(d,J=2.3Hz,1H),8.91(s,1H),8.52(d,J=2.3Hz,1H),8.43(d,J=5.3Hz,1H),8.32-8.26(m,1H),7.51-7.45(m,2H),7.24(d,J=5.3Hz,1H),6.67(d,J=15.4Hz,1H),5.39(d,J=52.8Hz,1H),4.16-3.90(m,5H),3.77(d,J=16.9Hz,9H),2.65(s,4H),2.39(td,J=16.2,15.5,6.5Hz,1H),2.28-2.13(m,1H).
实施例11:化合物S11的制备
中间体11-1的制备:
将S10(50mg,0.09mmol)溶于四氢呋喃和水中,向其中加入水和氢氧化锂(11mg,0.26mmol),待反应结束后,用1M盐酸将PH调至5-6,用乙酸乙酯萃取三次,旋干有机溶剂,得到化合物11-1粗品。
S11的制备:
将11-1溶于DMF中,向其中加入11-2(邻苯二胺)(22.5mg,0.21mmol),HOBT(27.5mg,0.20mmol),EDCI(37.5mg,0.20mmol),DIPEA(0.088ml,0.35mmol),室温反应,待反应结束后,使用水和二氯甲烷萃取,旋干有机层,柱层析纯化。1H NMR(400MHz,氘代甲醇)δ9.04(d,J=2.4Hz,1H),8.88(d,J=2.3Hz,1H),8.55(d,J=2.3Hz,1H),8.43(d,J=5.3Hz,1H),8.25(dd,J=8.5,2.6Hz,1H),7.49(dd,J=11.9,3.2Hz,2H),7.26(d,J=5.3Hz,1H),7.18(dd,J=7.9,1.3Hz,1H),7.07-6.98(m,1H),6.88-6.81(m,2H),6.71(td,J=8.0,1.4Hz,1H),5.49-5.30(m,1H),4.19-3.86(m,4H),3.81-3.64(m,5H),2.59(s,4H),2.45-2.09(m,3H).
实施例12:化合物S12的制备
将化合物2-1(60mg,0.13mmol)和化合物12-1(62mg,0.33mmol)溶于二氯甲烷溶液中,于冰浴下加入NaBH(OAc)3(110mg,0.52mmol),移至室温反应,待结束后用饱和碳酸氢钠溶液碱化,乙酸乙酯萃取,旋干有机相,柱层析分离。1H NMR(500MHz,氘代氯仿)δ8.99(d,J=2.1Hz,1H),8.79-8.69(m,1H),8.42(dd,J=16.5,3.6Hz,2H),8.24-8.16(m,1H),7.39(d,J=8.0Hz,2H),7.04(d,J=5.2Hz,1H),5.38(d,J=52.4Hz,1H),5.04(s,1H),4.26-3.93(m,4H),3.66(s,2H),3.22(s,2H),2.71-2.38(m,10H),2.23-2.05(m,2H),1.44(s,9H).
实施例13:化合物S13的制备
中间体13-1的制备:
将S12(60mg,0.10mol)溶于二氯甲烷中,加入三氟乙酸(1ml),待反应完全后,旋干溶剂,除去三氟乙酸残留,得到化合物13-1。
S13的制备:
将化合物13-1(20mg,0.04mmol)溶于二氯甲烷,向其中加入金刚烷乙酸(10mg,0.05mmol),EDCI(15mg,0.06mmol),DMAP(1mg,0.01mmol)和DIPEA(0.03ml,0.17mmol),室温反应3h。用水和二氯甲烷萃取,旋干有机相,柱层析纯化。1H NMR(400MHz,氘代二甲亚砜)δ8.97(d,J=2.3Hz,1H),8.79(s,1H),8.41(dd,J=16.7,3.7Hz,2H),8.21(s,1H),7.65(s,1H),7.37(d,J=8.7Hz,1H),7.05(d,J=5.2Hz,1H),6.88(s,1H),5.38(d,J=52.1Hz,1H),4.28-3.88(m,4H),3.74(s,2H),3.48(s,2H),2.85(d,J=36.2Hz,10H),2.52-2.35(m,1H),2.27-2.02(m,1H),1.93(s,2H),1.63(d,J=17.5Hz,14H).
实施例14:化合物S14的制备
将化合物2-1(20mg,0.04mmol)和14-1(39mg,0.05mmol)溶于DMF中,向其中加入碳酸钾(98.3mg,0.13mmol),室温反应,待反应结束后,水和乙酸乙酯萃取,旋干有机相,柱层析纯化。1H NMR(400MHz,氘代甲醇)δ8.92(d,J=2.4Hz,1H),8.83-8.78(m,2H),8.41(d,J=2.4Hz,1H),8.36(d,J=5.3Hz,1H),8.17(dd,J=8.5,2.6Hz,1H),7.88(s,1H),7.43-7.30(m,5H),7.15(d,J=5.3Hz,1H),5.36(d,J=52.9Hz,1H),4.62(s,1H),4.59-4.42(m,4H),4.30(d,J=15.5Hz,1H),4.13-3.94(m,3H),3.92-3.63(m,6H),3.62-3.51(m,11H),2.63-2.46(m,10H),2.41(s,3H),2.27-2.01(m,4H),1.00(s,9H).
实施例15:化合物S15的制备
将化合物2-1(20mg,0.04mmol)和15-1(41mg,0.05mmol)溶于DMF中,向其中加入碳酸钾(98.3mg,0.13mmol),室温反应,待反应结束后,水和乙酸乙酯萃取,旋干有机相,柱层析纯化。1H NMR(400MHz,氘代甲醇)δ8.95(d,J=2.5Hz,1H),8.86(d,J=8.9Hz,2H),8.44(d,J=2.5Hz,1H),8.38(d,J=5.3Hz,1H),8.22(dd,J=8.5,2.7Hz,1H),7.90(s,1H),7.46-7.34(m,5H),7.19(d,J=5.3Hz,1H),5.52-5.28(m,1H),4.69(s,1H),4.61-4.47(m,4H),4.35(d,J=15.5Hz,1H),4.13-4.01(m,5H),3.75-3.61(m,15H),3.12-2.63(m,12H),2.44(s,3H),2.35-2.02(m,4H),1.03(s,9H).
实施例16:化合物S16的制备
将化合物2-1(20mg,0.04mmol)和16-1(41.6mg,0.05mmol)溶于DMF中,向其中加入碳酸钾(98.3mg,0.13mmol),室温反应,待反应结束后,水和乙酸乙酯萃取,旋干有机相,柱层析纯化。1H NMR(400MHz,氘代甲醇)δ8.95(dd,J=7.6,4.6Hz,1H),8.86(d,J=12.4Hz,2H),8.49-8.37(m,2H),8.24(s,1H),7.90(s,1H),7.47-7.34(m,5H),7.26-7.18(m,1H),5.39(d,J=52.8Hz,1H),4.67-4.46(m,4H),4.33(d,J=15.5Hz,1H),4.09(dd,J=23.8,13.7Hz,3H),3.90(dd,J=14.7,10.3Hz,4H),3.83-3.66(m,8H),3.61(s,9H),3.01-2.84(m,5H),2.73(s,2H),2.61-2.30(m,7H),2.29-2.02(m,4H),1.03(s,9H).
实施例17:化合物S17的制备
将化合物2-1(20mg,0.04mmol)和17-1(43.24mg,0.05mmol)溶于DMF中,向其中加入碳酸钾(98.3mg,0.13mmol),室温反应,待反应结束后,水和乙酸乙酯萃取,旋干有机相,柱层析纯化。1H NMR(400MHz,氘代甲醇)δ8.93(d,J=2.4Hz,1H),8.86(d,J=9.0Hz,2H),8.42(d,J=2.4Hz,1H),8.38(d,J=5.3Hz,1H),8.26-8.17(m,1H),7.90(s,1H),7.46-7.34(m,5H),7.18(d,J=5.3Hz,1H),5.38(d,J=53.0Hz,1H),4.68(s,1H),4.62-4.48(m,4H),4.34(d,J=15.5Hz,2H),4.15-3.95(m,5H),3.94-3.57(m,19H),3.05-2.88(m,7H),2.74(s,4H),2.44(s,3H),2.41-2.04(m,4H),1.03(s,9H).
实施例18:化合物S18的制备
将化合物2-1(20mg,0.04mmol)和18-1(46.3mg,0.05mmol)溶于DMF中,向其中加入碳酸钾(98.3mg,0.13mmol),室温反应,待反应结束后,水和乙酸乙酯萃取,旋干有机相,柱层析纯化。1H NMR(400MHz,氘代甲醇)δ8.98(d,J=2.4Hz,1H),8.83(s,2H),8.49(d,J=2.4Hz,1H),8.39(d,J=5.3Hz,1H),8.20(dd,J=8.5,2.6Hz,1H),7.88(s,1H),7.44-7.32(m,5H),7.21(d,J=5.3Hz,1H),5.48-5.27(m,1H),4.66-4.43(m,5H),4.30(d,J=15.5Hz,1H),4.15-3.97(m,4H),3.97-3.83(m,4H),3.78-3.64(m,3H),3.64-3.52(m,19H),2.57(s,10H),2.42(s,5H),2.28-1.97(m,4H),1.01(s,9H).
实施例19:化合物S19的制备
将化合物13-1(30mg,0.06mmol)和19-1(42.5mg,0.07mmol)溶于DMF中,加入HATU(34.2mg,0.09mmol)和DIPEA(0.04ml,0.24mmol),室温反应,待反应结束后,水和乙酸乙酯萃取,旋干有机相,柱层析纯化。1H NMR(400MHz,氘代甲醇)δ9.00(d,J=2.3Hz,1H),8.93(s,2H),8.85(s,1H),8.51(d,J=2.4Hz,1H),8.42(d,J=5.3Hz,1H),8.29(s,1H),7.48-7.36(m,5H),7.25(d,J=5.4Hz,1H),5.47-5.33(m,1H),4.71-4.35(m,5H),4.14-3.71(m,18H),3.41(q,J=6.8Hz,2H),2.90-2.58(m,10H),2.44(s,3H),2.41-2.02(m,5H),1.07-0.97(d,J=9.1Hz,9H),0.93-0.87(m,1H).
实施例20:化合物S20的制备
将化合物13-1(30mg,0.06mmol)和20-1(51.76mg,0.07mmol)溶于DMF中,加入HATU(34.2mg,0.09mmol)和DIPEA(0.04ml,0.24mmol),室温反应,待反应结束后,水和乙酸乙酯萃取,旋干有机相,柱层析纯化。1H NMR(400MHz,氘代甲醇)δ9.02(d,J=2.4Hz,1H),8.88-8.84(m,2H),8.52(d,J=2.4Hz,1H),8.43(d,J=5.3Hz,2H),8.23(dd,J=8.5,2.6Hz,1H),7.47-7.35(m,5H),7.24(d,J=5.3Hz,1H),5.40(dt,J=52.4,3.3Hz,1H),4.62-4.46(m,4H),4.34(d,J=15.5Hz,2H),4.16-4.04(m,3H),3.99(s,3H),3.97-3.85(m,3H),3.78(dd,J=11.0,3.9Hz,1H),3.71-3.58(m,10H),3.52(t,J=5.6Hz,3H),3.42-3.33(m,5H),2.65-2.46(m,14H),2.45(s,3H),2.42-1.99(m,4H),1.02(s,9H).
实施例21:化合物S21的制备
将化合物13-1(30mg,0.06mmol)和21-1(55mg,0.07mmol)溶于DMF中,加入HATU(34.2mg,0.09mmol)和DIPEA(0.04ml,0.24mmol),室温反应,待反应结束后,水和乙酸乙酯萃取,旋干有机相,柱层析纯化。1H NMR(400MHz,氘代甲醇)δ8.98(d,J=2.4Hz,1H),8.93-8.80(m,2H),8.48(d,J=2.4Hz,2H),8.40(d,J=5.3Hz,1H),8.22(dd,J=8.5,2.6Hz,1H),7.48-7.36(m,5H),7.21(d,J=5.3Hz,1H),5.49-5.29(m,1H),4.67-4.45(m,4H),4.33(d,J=15.5Hz,5H),4.18-3.84(m,6H),3.78(dd,J=11.0,3.9Hz,1H),3.72-3.54(m,12H),3.51(t,J=5.5Hz,3H),3.39(t,J=6.7Hz,3H),3.35(s,4H),2.67-2.40(m,17H),2.40-1.99(m,4H),1.02(s,9H).
实验例:化合物的TBK1激酶抑制活性测试
采用invitrogen公司的Z-LYTE’Kinase Assay Kit-Ser/Thr 5peptide(Cat.no.PV3178)试剂盒及TBK1 Recombinant Human Protein(Cat.no.A31534)进行分子水平激酶抑制活性检测。该测试方法基于荧光共振能量转移(FRET)原理,在底物肽段两端分别连接有两个荧光基团:香豆素和荧光素,底物肽段可以正常发生FRET。当有ATP和TBK1激酶存在时,TBK1可以催化底物肽段在特定位点发生磷酸化。磷酸化的底物将不可被后续加入的蛋白酶分解而继续保持FERT特性;未被磷酸化的底物将被蛋白酶水解为2段,这时两端的荧光基团之间将无法发生FRET(活性测定原理请见图1)。
通过检测反应体系荧光基团分别在特定波长下的荧光发射强度,可以通过计算Emission Ratio值定量反应体系FRET程度的高低,进而可以计算出不同体系中具体的TBK1活性。本申请的个别化合物的TBK1激酶抑制活性测试结果如下表1所示。
表1
*与该专利化合物同批测试结果
TBK1激酶抑制活性测试结果显示:多数化合物对TBK1酶具有高抑制活性,近一半化合物表现出强于WO2018154315专利申请中优势化合物(实施例2)的活性。其中化合物S12的激酶抑制活性最好,IC50=0.1nM,是同批测试的阳性化合物(IC50=20nM)活性的200倍;化合物S11的激酶抑制活性IC50=0.6nM,较同批测试的阳性化合物活性高出30倍以上。由此可见,本申请的化合物在末端哌嗪氮原子上引入多元化取代后,化合物对TBK1酶的抑制活性可增强几十至数百倍。
Claims (10)
1.一种由以下通式I表示的化合物或其药学上可接受的盐:
在以上通式I中,
Z选自C1-C8亚烷基;
Q选自含有1~3个选自N、O、S杂原子的5~8元杂环基,所述杂环基包括单环、并环、桥环、螺环;
Y选自-C(=O)-R1,-(CH2)m-R2或-L-X,
其中,R1选自取代或未取代的C1-C6烷氧基、取代或未取代的C2-C6炔基、取代或未取代的C2-C6烯基、取代或未取代的5-10元杂芳基,所述取代的取代基选自卤素、C1-C6烷氧酰基、5-7元杂环基、(2-氨基苯基)胺甲酰基;
m为1-4的整数,
R2选自取代或未取代的C6-C10芳基、-NHC(=O)-R3,其中,C6-C10芳基的取代基选自未取代或被卤素取代的磺酰基,R3选自C1-C6烷氧基、未取代或金刚烷取代的C1-C6烷基;
L选自-[-(CH2)2-O]n-(CH2)f-、
-(CH2)n-NH-C(=O)-CH2-O-(CH2)2-O-CH2-、
-(CH2)n-NH-C(=O)-CH2-[O-(CH2)2]p-NH-C(=O)-(CH2)q-,其中n、f、p和q各自独立地为0至6的整数,
X为
2.根据权利要求1所述的化合物或其药学上可接受的盐,其中,Z选自C1-C4亚烷基;
Q选自哌嗪环,
Y选自-C(=O)-R1,-(CH2)m-R2或-L-X,
其中,R1选自取代或未取代的C1-C4烷氧基、取代或未取代的C2-C4炔基、取代或未取代的C2-C4烯基、取代或未取代的5-10元杂芳基,所述取代的取代基选自C1-C4烷氧酰基、吗啉基、(2-氨基苯基)胺甲酰基;
m为1-4的整数,
R2选自取代或未取代的苯基、-NHC(=O)-R3,其中,苯基的取代基选自未取代或被卤素取代的磺酰基,R3选自C1-C4烷氧基、未取代或金刚烷取代的C1-C4烷基;
L选自-[-(CH2)2-O]n-(CH2)f-、-(CH2)n-NH-C(=O)-CH2-O-(CH2)2-O-CH2-、-(CH2)n-NH-C(=O)-CH2-[O-(CH2)2]p-NH-C(=O)-(CH2)q-,其中n、f、p和q各自独立地为0至6的整数,
X为
3.根据权利要求1所述的化合物或其药学上可接受的盐,其中,Z选自C1-C4亚烷基;
Q选自
Y选自-C(=O)-R1,-(CH2)m-R2或-L-X,
其中,R1选自取代或未取代的甲氧基,取代或未取代的乙氧基,取代或未取代的叔丁氧基,取代或未取代的乙炔基,取代或未取代的丙炔基,取代或未取代的乙烯基,取代或未取代的丙烯基,取代或未取代的所述取代的取代基选自氟、氯、溴、甲氧酰基、乙氧酰基、吗啉基、(2-氨基苯基)胺甲酰基;
m为1-4的整数,
R2选自取代或未取代的苯基、-NHC(=O)-R3,其中,苯基的取代基选自未取代或被卤素取代的磺酰基,R3选自甲氧基、乙氧基、叔丁氧基、甲基、乙基、金刚烷取代的甲基、金刚烷取代的乙基;
L选自-[-(CH2)2-O]n-(CH2)f-、
-(CH2)n-NH-C(=O)-CH2-O-(CH2)2-O-CH2-、
-(CH2)n-NH-C(=O)-CH2-[O-(CH2)2]p-NH-C(=O)-(CH2)q-,其中n、f、p和q各自独立地为0至6的整数,
X为
4.根据权利要求1-3任一项所述的化合物或其药学上可接受的盐,其中,Z为C1-C4亚烷基;
Q选自
Y的定义分别如权利要求1-3中任一项所定义。
5.根据权利要求1-3任一项所述的化合物或其药学上可接受的盐,其中,Z为-CH2-;
Q为
Y的定义分别如权利要求1-3中任一项所定义。
6.根据权利要求1所述的化合物或其药学上可接受的盐,其中,
所述通式I的化合物由以下通式II表示:
其中,在上述通式II中,L和X的定义分别同权利要求1中所定义。
7.根据权利要求1所述的化合物或其药学上可接受的盐,其中,所述化合物选自以下化合物之一:
8.一种药物组合物,其至少包含如权利要求1至7中任一项所述的化合物或其药学上可接受的盐作为药物活性组分,以及药学上可接受的载体。
9.如权利要求1至7中任一项所述的化合物或其药学上可接受的盐,或如权利要求8所述的药物组合物在制备用作TBK1抑制剂的药物中的用途。
10.根据权利要求9所述的用途,其中,所述TBK1抑制剂用于恶性肿瘤、自身免疫及炎症疾病的治疗。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110280860.5A CN115073425B (zh) | 2021-03-16 | 2021-03-16 | 一类作为tbk1抑制剂的化合物、包含其的药物组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110280860.5A CN115073425B (zh) | 2021-03-16 | 2021-03-16 | 一类作为tbk1抑制剂的化合物、包含其的药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115073425A CN115073425A (zh) | 2022-09-20 |
CN115073425B true CN115073425B (zh) | 2023-11-14 |
Family
ID=83246414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110280860.5A Active CN115073425B (zh) | 2021-03-16 | 2021-03-16 | 一类作为tbk1抑制剂的化合物、包含其的药物组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115073425B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102007124A (zh) * | 2008-02-15 | 2011-04-06 | 里格尔制药公司 | 嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途 |
WO2013173506A2 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
CN105189480A (zh) * | 2013-02-21 | 2015-12-23 | 多曼尼克斯公司 | 在治疗由IKKε和/或TBK-1机制介导的疾病中有用的嘧啶化合物 |
WO2018154315A1 (en) * | 2017-02-23 | 2018-08-30 | Domainex Limited | 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitrile compounds as ikke, tbk1 and/or sik2 kinases inhibitors |
-
2021
- 2021-03-16 CN CN202110280860.5A patent/CN115073425B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102007124A (zh) * | 2008-02-15 | 2011-04-06 | 里格尔制药公司 | 嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途 |
WO2013173506A2 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
CN105189480A (zh) * | 2013-02-21 | 2015-12-23 | 多曼尼克斯公司 | 在治疗由IKKε和/或TBK-1机制介导的疾病中有用的嘧啶化合物 |
WO2018154315A1 (en) * | 2017-02-23 | 2018-08-30 | Domainex Limited | 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitrile compounds as ikke, tbk1 and/or sik2 kinases inhibitors |
Also Published As
Publication number | Publication date |
---|---|
CN115073425A (zh) | 2022-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3573983B1 (en) | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor | |
JP6617155B6 (ja) | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 | |
NL8202626A (nl) | Derivaten van 9-(2-hydroxyethoxymethyl)guanine. | |
CA2549628C (en) | Fused pyrrolocarbazoles and methods for the preparation thereof | |
CN111961034A (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
CN107383004B (zh) | 2-氨基咪唑并吡啶类衍生物及制备和应用 | |
EP3741758A1 (en) | Bromodomain inhibitor compound and use thereof | |
JP2017537933A (ja) | 新規な抗菌性化合物 | |
JP2021522317A (ja) | ヒストンアセチルトランスフェラーゼ(hat)阻害剤及びその用途 | |
CN116546985A (zh) | 吡啶并嘧啶类衍生物及其制备方法和用途 | |
CA2898274A1 (en) | Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method | |
CN112479988B (zh) | 取代联苯类化合物及其制备方法、用途和药物组合物 | |
CN115073425B (zh) | 一类作为tbk1抑制剂的化合物、包含其的药物组合物及其用途 | |
CN110028508B (zh) | 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂 | |
JP2019505495A (ja) | 置換ナフタレンジイミドおよびその使用 | |
Lizhuo et al. | Synthesis, antibacterial and antifungal evaluation of rhodanine derivatives bearing quinoxalinyl imidazole moiety as ALK5 inhibitors | |
CN114591339B (zh) | 一类Toll样受体抑制剂及其制备和应用 | |
CN107827908B (zh) | 一种雷帕霉素三氮唑衍生物及其制备方法和用途 | |
CN114437113B (zh) | 一种噻唑并吡啶环联三氮唑类化合物及其制备方法和应用 | |
JP6900406B2 (ja) | Akt阻害剤としてのジヒドロピラゾロアゼピン系化合物 | |
EP3275882B1 (en) | Process of synthesizing substituted pyridine and pyrimidine compound | |
CN112839931B (zh) | 1,2,3,4-四氢喹喔啉衍生物及其制备方法和应用 | |
CN114478403A (zh) | 一种含芳香胍基类化合物及其制备方法与应用 | |
CN111606888B (zh) | 吡咯类衍生物及其制备方法与应用 | |
CN117479934A (zh) | 用于治疗肾纤维化的噁二唑基二氢吡喃并[2,3-b]吡啶的HIPK2抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |